Charles River Lbrtrs ntrntl Inc (N:CRL)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 251 Ballardvale St
WILMINGTON MA 01887
Tel: N/A
Website: https://www.criver.com
IR: See website
<
Key People
James C. Foster
Chairman of the Board, President, Chief Executive Officer
Flavia H. Pease
Chief Financial Officer, Corporate Executive Vice President
Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Victoria L. Creamer
Corporate Executive Vice President and Chief People Officer
William D. Barbo
Executive Vice President, Strategic Advisor
Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment Management
Kristen Eisenhauer
Senior Vice President, Chief Commercial Officer
 
Business Overview
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Financial Overview
For the fiscal year ended 30 December 2023, Charles River Lbrtrs ntrntl Inc revenues increased 4% to $4.13B. Net income decreased 2% to $474.6M. Revenues reflect Discovery And Safety Assessment segment increase of 7% to $2.62B, Research Models segment increase of 7% to $792.3M, Canada segment increase of 22% to $487.3M, Europe segment increase of 4% to $1.08B, Asia Pacific (Region) segment increase of 4% to $200.8M.
Employees: 20,000 as of Dec 30, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $16,289M as of Dec 30, 2023
Annual revenue (TTM): $4,129M as of Dec 30, 2023
EBITDA (TTM): $967.26M as of Dec 30, 2023
Net annual income (TTM): $474.62M as of Dec 30, 2023
Free cash flow (TTM): $365.37M as of Dec 30, 2023
Net Debt Last Fiscal Year: $2,376M as of Dec 30, 2023
Shares outstanding: 51,349,770 as of Jan 27, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.